TORONTO — Biovail Corporation (NYSE: BVF) (TSX: BVF) announced today that it has received Approval from the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for Aplenzin[TM] (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults.
Aplenzin[TM] is an alcohol-resistant formulation of a new bupropion salt and has been approved in 174mg, 348mg, and 522mg extended-release tablets. The 522mg dosage strength provides patients requiring the maximum allowable dose of bupropion the only single tablet, once-daily option.
Related Results
Smoking cessation drug may be helpful for nicotine addiction in schizophrenics.
Steady-state clinical pharmacokinetics of bupropion extended-release in youth…
Sporting Digest: drugs in sport
BCMA Calls for Tobacco Tax to Fund Stop-Smoking Programs.
Biovail Announces Receipt Of An Approvable Letter For Wellbutrin XL.
Biovail remains in active partnership discussions for the commercialization rights for Aplenzin[TM] in the United States.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the Company’s Web site at www.biovail.com.
For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com.
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning